Semaglutide

Full results from Novo Nordisk's EVOKE and EVOKE+ trials, published in The Lancet, show oral semaglutide had no effect on cognitive decline over two years despite reducing key cerebrospinal fluid markers of neuroinflammation and tau pathology by roughly 10 percent.

The US government's health research agency has funded the first large-scale clinical trials testing whether rapamycin, semaglutide, and other repurposed drugs can slow biological aging in healthy adults, with results expected within three years.

The FDA cited Novo Nordisk for serious violations of adverse event reporting requirements after a 2025 inspection found the company failed to report three patient deaths linked to semaglutide, including one suicide, and lacked adequate procedures for post-marketing drug safety surveillance.